Lowest Price Guaranteed From USD 4,799
Published
July 2021
Pages
495
View Count
20779
Example Insights
-thumb.PNG) |
 |
-thumb.PNG) |
 |
 |
-thumb.PNG) |
-thumb.PNG) |
 |
-thumb.PNG) |
 |
 |
Report Description
The pharmaceutical CMO market is estimated to be worth around $83 billion in 2022 and is expected to grow at compounded annual growth rate (CAGR) of 6.6% during the forecast period. At present, the pharmaceutical industry is dominated by the presence of small molecule products, which represent close to 80% of the overall pipeline. Even though biologics have shown significant promise in the treatment of a wide range of disorders, in recent years, approval of novel small molecules has been on the rise. In fact, in 2020, over 50 small molecule drugs were approved by the US FDA, while around 8,000 such candidates are being evaluated across different stages of development. It is worth mentioning that the pipeline features increasingly complex candidates, which require specialized facilities, advanced equipment and operational expertise. As setting-up / acquiring manufacturing capabilities is both time and cost intensive process, it is extremely challenging for pharmaceutical companies to perform development and manufacturing operations independently. The aforementioned constraints, coupled to the rising demand for safer and effective drugs (currently driven by the COVID-19 pandemic), have prompted players to outsource a significant portion of their business segments to contract manufacturing organizations (CMOs), and contract development and manufacturing organizations (CDMOs).
The current landscape of pharmaceutical contract service providers is highly fragmented, featuring a mix of start-ups, mid-sized firms and established players. The inherent expertise of CMOs and CDMOs is believed to be capable of enabling reduction in the time-to-market a product, significant cost-benefits, as well as access to larger production capacities and novel technologies. It is worth mentioning that there has been substantial merger and acquisition activity in the pharmaceutical contract manufacturing market in the past few years, as players strive to become one stop shops, in order to cater to the diverse needs of pharmaceutical developers (ranging from early-stage development to commercial production). Considering the ongoing innovation in production technologies, evolving pipeline of small molecule products and the increasing demand for such drug candidates, we believe that the pharmaceutical contract manufacturing market is likely to witness positive growth in the coming years.
The “Pharmaceutical Contract Manufacturing Market (3rd Edition) Distribution by key business segments (API(s) and FDF(s)), type of API(s) manufactured (branded and generic), type of FDF(s) offered (oral solids, parenteral and others), type of primary packaging form (blisters, bottles, injectables and others), scale of operation (clinical and commercial), type of end-users (small pharmaceutical companies, mid-sized pharmaceutical companies and large pharmaceutical companies) and key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa: Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing industry. Amongst the other elements, the report features:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market based on several parameters, such as growth of the overall pharmaceutical market, cost of goods sold, direct manufacturing costs. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. The report also features the likely distribution of the opportunity across [A] key business segments (API(s) and FDF(s)), [B] type of API(s) manufactured (branded and generic), [C] type of FDF(s) offered (oral solids, parenteral and others), [D] type of primary packaging form (blisters, bottles, injectables and others), [E] scale of operation (clinical and commercial), [F] type of end-users (small pharmaceutical companies, mid-sized pharmaceutical companies and large pharmaceutical companies) and [G] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. In order to account for future uncertainties and add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the pharmaceutical contract manufacturing market in the mid-long term.
Chapter 3 provides a general introduction to various type of manufacturers engaged in the pharmaceutical market. It further includes a brief overview of the concept of contract manufacturing, featuring a discussion on the evolution of contract services in this industry. Additionally, it highlights details related to the need for outsourcing in this domain. Further, the chapter includes a brief overview of contract manufacturing models that have been adopted in the pharmaceutical industry and an exhaustive list of services offered by CMOs; the chapter concludes with a discussion on the challenges associated with the outsourcing of pharmaceutical manufacturing operations.
Chapter 4 features a detailed discussion on various guidelines laid down by major regulatory bodies, across different countries, featuring an elaborative assessment of over 450 CMOs engaged in this domain, along with information on their operational approvals, certifications received, and relative popularity of the key regulatory body. Additionally, the chapter features an insightful multi-dimensional bubble analysis, presenting a comparison of the current regulatory scenario in key geographies
Chapter 5 provides a detailed overview of the overall market landscape, featuring an elaborate list of over 450 active CMOs engaged in this domain, along with information on several relevant parameters, such as year of establishment, company size, geographical location of CMOs, type of business segment (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of API(s) manufactured (complex, generic and sterile), type of FDF(s) offered (oral solids, liquids / semi-solids, injectables, inhalation and others), type of service(s) offered, type of primary packaging form (blister, tubes, vial / cartridge, ampoule, sachets / pouches / bags, inhalers / nasal sprays, glass / plastic / dropper bottles, pre-filled syringes / autoinjectors), scale of operation (preclinical, clinical and commercial) and specific location of manufacturing facilities (country-wise).
Chapter 6 presents a detailed analysis of pharmaceutical contract manufacturing service providers’ capabilities in different regions, based on several relevant parameters, such as type of business segment, type of service(s) offered and type of packaging form.
Chapter 7 features elaborate profiles of key players engaged in offering pharmaceutical contract manufacturing services. Each profile features a brief overview of the company, along with information on its financial performance (if available), service(s) portfolio, manufacturing facilities and capabilities, recent developments and an informed future outlook.
Chapter 8 presents a qualitative analysis highlighting the various factors that need to be taken into consideration by pharmaceutical drug developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
Chapter 9 presents a detailed analysis of various mergers and acquisitions that have taken place in this domain, highlighting the trend in number of companies acquired and geographical distribution of the activity, during the period 2017-2021. Further, it highlights the relationship between deal multiples (based on revenues), number of employees and experience of the acquired firm.
Chapter 10 features A detailed analysis of the recent expansions (since 2017) undertaken by various service providers in order to augment their respective pharmaceutical contract manufacturing service portfolios, based on a several relevant parameters, such as year of expansion, purpose of expansion (capability expansion, capacity expansion, facility expansion, new facility), type of business segment (API(s), FDF(s)), capital invested, scale of operation (clinical, commercial), type of service(s) offered (formulation, manufacturing, packaging), geographical location of facility, and most active players (in terms of number of instances).
Chapter 11 features an estimate of the global, installed capacity for the manufacturing of small-molecule drugs, based on information provided by various industry stakeholders in the public domain. It also features distribution of the available capacity on the basis of scale of operation (clinical and commercial), company size (small, mid-sized and large firms) and key geographical regions (North America, Europe and Asia Pacific). Overall, the analysis represents a holistic view of the supply-side of the market, allowing us to present an informed opinion on whether the present capacity will be able to meet the likely future demand.
Chapter 12 provides informed estimates of the annual clinical and commercial demand for small molecule drugs, across key geographical regions, based on relevant parameters, such as number of patient population, dosage and dose frequency.
Chapter 13 represents a detailed market forecast, highlighting the future potential of the pharmaceutical contract manufacturing market, till 2030. Additionally it features the likely distribution of the opportunity across different [A] key business segments (API(s) and FDF(s)), [B] type of API(s) manufactured (branded and generic), [C] type of FDF(s) offered (oral solids, parenteral and others), [D] type of primary packaging form (blisters, bottles, injectables and others), [E] scale of operation (clinical and commercial), [F] type of end-users (large pharmaceutical companies, mid-sized pharmaceutical companies and small pharmaceutical companies) and [G] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa.
Chapter 14 presents a detailed analysis of various pharmaceutical contract manufacturing service providers featuring schematic representations, including [A] a heat map analysis, highlighting the distribution of integrated contract service providers (companies offering manufacturing services for both small and large molecules), on the basis of location of their headquarters, year of establishment and number of employees, [B] a geographical landscape analysis, highlighting CMOs that have a wide geographical reach, on the basis of their presence (manufacturing facilities) across various regions, and [C] a grid representation, highlighting the global and regional trend of API and FDF outsourcing services, based on the location of headquarters of the company, number of employees, type of business segment, type of service(s) offered and scale of operation.
Chapter 15 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the pharmaceutical contract manufacturing market, under an elaborate SWOT framework. Further, it presents a schematic Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall pharmaceutical industry.
Chapter 16 is a case study highlighting a comparison of the key characteristics of large and small molecule drugs, along with information on the steps involved in their respective manufacturing processes.
Chapter 17 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.
Chapter 18 is a collection of executive insight(s) of the discussion(s) that were held with key stakeholder(s) in this market. We have presented details of interviews held with Scott Goldstein (Ex - Director, Business Development, Ajinomoto Bio-Pharma Services), Thomas Früh (Ex - CEO, Bachem), Bhaskar Venepalli (President and CEO, CiVentiChem), Roberto Margarita (Director, Business Development, CordenPharma), Allison Vavala (Director, Commercial Development, Helsinn Group), Kevin Daley (Director, Pharmaceuticals Marketing, Novasep), Piyush Desai (Director, Operations, Sovereign Pharma), Ilan Avni (Vice President Business Development, Marketing, and IP, Wavelength Pharmaceuticals).
Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 20 is an appendix, which provides the list of companies and organizations included in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Manufacturers
3.3. Overview of Pharmaceutical Contract Manufacturing
3.4. Evolution of Pharmaceutical Contract Manufacturing
3.4.1. Traditional Pharmaceutical CMOs
3.4.2. Modern Pharmaceutical CMOs
3.5. Need for Outsourcing in the Pharmaceutical Industry
3.6. Recent Trends in the Pharmaceutical Contract Manufacturing Industry
3.6.1. Tactical Partnerships
3.6.2. Integrated End-to-End Business Model
3.6.3. Software Service Providers
3.7. Services Offered by CMOs
3.8. Key Considerations While Selecting a CMO Partner
3.9. Risks and Challenges Associated with Outsourcing Pharmaceutical Manufacturing Operations
4. REGULATORY LANDSCAPE FOR PHARMACEUTICAL CONTRACT MANUFACTURERS
4.1. Chapter Overview
4.2. Regulatory Guidelines in North America
4.2.1. The US Scenario
4.2.2. Canadian Scenario
4.3. Regulatory Guidelines in Europe
4.4. Regulatory Guidelines in Asia-Pacific and Rest of the World
4.4.1. Chinese Scenario
4.4.2. Indian Scenario
4.4.3. Japanese Scenario
4.4.4. South Korean Scenario
4.4.5 Australian Scenario
4.4.6. Brazilian Scenario
4.5. Analysis of Pharmaceutical CMOs by Approval Received from Regulatory Authorities
4.6. Regional Summary of Regulatory Scenario (Bubble Analysis)
5. PHARMACEUTICAL CMOs: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Pharmaceutical CMOs: List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Business Segment
5.2.5. Analysis by Type of API Manufactured
5.2.6. Analysis by Type of FDF Offered
5.2.7. Analysis by Type of Molecule
5.2.8. Analysis by Type of Service(s) Offered
5.2.9. Analysis by Type of Primary Packaging Form Offered
5.2.10. Analysis by Scale of Operation
5.2.11. Analysis by Location of Manufacturing Facility
5.2.11.1 Pharmaceutical Contract Manufacturing Facilities in North America
5.2.11.2 Pharmaceutical Contract Manufacturing Facilities in Europe
5.2.11.3 Pharmaceutical Contract Manufacturing Facilities in Asia-Pacific and Rest of the World
6. REGIONAL CAPABILITY
6.1. Chapter Overview
6.2. Key Assumptions and Methodology
6.3. Regional Capability Analysis of Pharmaceutical CMOs
6.3.1 Analysis of CMOs based in North America
6.3.2. Analysis of CMOs based in Europe
6.3.3. Analysis of CMOs based in Asia-Pacific and Rest of the World
7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Key Benefits Key Benefits Offered by the One-Stop-Shop Model
7.3 Profiles of Players Operating as One-Stop-Shops
7.4. North America
7.4.1. AMRI Global
7.4.1.1. Company Overview
7.4.1.2. Service Portfolio
7.4.1.3. Manufacturing Capabilities and Facilities
7.4.1.4. Recent Developments and Future Outlook
7.4.2. Altasciences
7.4.2.1. Company Overview
7.4.2.2. Service Portfolio
7.4.2.3. Manufacturing Capabilities and Facilities
7.4.2.4. Recent Developments and Future Outlook
7.4.3. Cambrex
7.4.3.1. Company Overview
7.4.3.2. Service Portfolio
7.4.3.3. Manufacturing Capabilities and Facilities
7.4.3.4. Recent Developments and Future Outlook
7.4.4. Catalent
7.4.4.1. Company Overview
7.4.4.2. Financial Information
7.4.4.3. Service Portfolio
7.4.4.4. Manufacturing Capabilities and Facilities
7.4.4.5. Recent Developments and Future Outlook
7.4.5. DPT Laboratories
7.4.5.1. Company Overview
7.4.5.2. Service Portfolio
7.4.5.3. Manufacturing Capabilities and Facilities
7.4.5.4. Recent Developments and Future Outlook
7.4.6. Thermo Fisher Scientific
7.4.6.1. Company Overview
7.4.6.2. Financial Information
7.4.6.3. Service Portfolio
7.4.6.4. Manufacturing Capabilities and Facilities
7.4.6.5. Recent Developments and Future Outlook
7.5. Europe
7.5.1. Aenova Group
7.5.1.1. Company Overview
7.5.1.2. Financial Information
7.5.1.3. Service Portfolio
7.5.1.4. Manufacturing Capabilities and Facilities
7.5.1.5. Recent Developments and Future Outlook
7.5.2. Almac
7.5.2.1. Company Overview
7.5.2.2. Service Portfolio
7.5.2.3. Recent Developments and Future Outlook
7.5.3. Corden Pharma
7.5.3.1. Company Overview
7.5.3.2. Service Portfolio
7.5.3.3. Manufacturing Capabilities and Facilities
7.5.3.4. Recent Developments and Future Outlook
7.5.4. Fresenius Kabi
7.5.4.1. Company Overview
7.5.4.2. Financial Information
7.5.4.3. Service Portfolio
7.5.4.4. Manufacturing Capabilities and Facilities
7.5.4.5. Recent Developments and Future Outlook
7.5.5. Glatt
7.5.5.1. Company Overview
7.5.5.2. Service Portfolio
7.5.5.3. Manufacturing Capabilities and Facilities
7.5.5.4. Recent Developments and Future Outlook
7.5.6. Hovione
7.5.6.1. Company overview
7.5.6.2. Service Portfolio
7.5.6.3. Manufacturing Capabilities and Facilities
7.5.6.4. Recent Developments and Future Outlook
7.5.7. Recipharm
7.5.7.1. Company Overview
7.5.7.2. Financial Information
7.5.7.3. Service Portfolio
7.5.7.4. Manufacturing Capabilities and Facilities
7.5.7.5. Recent Developments and Future Outlook
7.5.8. Siegfried
7.5.8.1. Company Overview
7.5.8.2. Financial Information
7.5.8.3. Service Portfolio
7.5.8.4. Manufacturing Capabilities and Facilities
7.5.8.5. Recent Developments and Future Outlook
7.6. Asia-Pacific and Rest of the World
7.6.1. CMIC Group
7.6.1.1. Company Overview
7.6.1.2. Financial Information
7.6.1.3. Service Portfolio
7.6.1.4. Recent Developments and Future Outlook
7.6.2. Nectar Lifesciences
7.6.2.1. Company Overview
7.6.2.2. Financial Information
7.6.2.3. Service Portfolio
7.6.2.4. Manufacturing Capabilities and Facilities
7.6.2.5. Recent Developments and Future Outlook
7.6.3. Syngene
7.6.3.1. Company Overview
7.6.3.2. Financial Information
7.6.3.3. Service Portfolio
7.6.3.4. Manufacturing Capabilities and Facilities
7.6.3.5. Recent Developments and Future Outlook
7.6.4. WuXi AppTec
7.6.4.1. Company Overview
7.6.4.2. Financial Information
7.6.4.3. Service Portfolio
7.6.4.4. Manufacturing Capabilities and Facilities
7.6.4.5. Recent Developments and Future Outlook
8. MAKE VERSUS BUY DECISION FRAMEWORK
8.1. Chapter Overview
8.2. Assumptions and Key Parameters
8.3. Pharmaceutical Contract Manufacturers: Make versus Buy Decision Making
8.3.1. Scenario 1
8.3.2. Scenario 2
8.3.3. Scenario 3
8.3.4. Scenario 4
8.4. Concluding Remarks
9. MERGERS AND ACQUISITIONS
9.1. Chapter Overview
9.2. Merger and Acquisition Models
9.3. Pharmaceutical Contract Manufacturing: Mergers and Acquisitions
9.3.1. Cumulative Year-wise Trend
9.3.2. Analysis by Type of Agreement
9.3.3. Analysis by Type of Acquisition
9.3.4. Analysis by Focus Area
9.3.5. Analysis by Type of Business Segment
9.3.6. Analysis by Type of Service(s) Offered
9.3.7. Analysis by Scale of Operation
9.3.8. Analysis by Geography
9.3.9. Analysis by Location of Manufacturing Facility
9.3.10. Most Active Acquirers: Analysis by Number of Acquisitions
9.3.11. Analysis by Key Value Drivers
9.3.11.1. Analysis by Year of Acquisition and Key Value Drivers
9.4. Key Acquisitions: Analysis by Deal Multiples
10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Pharmaceutical Contract Manufacturing Market: Expansions
10.2.1. Cumulative Year-wise Distribution
10.2.2. Analysis by Purpose of Expansion
10.2.3. Analysis by Year and Purpose of Expansion
10.2.4. Analysis by Type of Business Segment
10.2.5. Analysis by Type of Molecule
10.2.6. Analysis by Type of Service(s) Offered
10.2.7. Analysis by Scale of Operation
10.2.8. Analysis by Capital Invested
10.2.9. Analysis by Location of Headquarters
10.2.10. Analysis by Purpose of Expansion and Location of Headquarters
10.2.11. Analysis by Location of Manufacturing Facility
10.2.12. Most Active Players: Analysis by Number of Recent Expansions
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Pharmaceutical Contract Manufacturing: Global Production Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Headquarters
11.3.3.1. Analysis of Capacity Installed in North America
11.3.3.2. Analysis of Capacity Installed in Europe
11.3.3.3. Analysis of Capacity Installed in Asia-Pacific
11.4. Concluding Remarks
12. DEMAND ANALYSIS
12.1. Chapter Overview
12.2. Key Assumptions and Methodology
12.3. Overall Annual Demand for Small Molecule APIs, 2021-2030
12.3.1. Analysis by Scale of Operation
12.4. Correlation Between Annual Demand and Capacity
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Pharmaceutical Contract Manufacturing Market, 2021-2030
13.3.1. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Business Segment
13.1.2. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of API Manufactured
13.1.3. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of FDF Offered
13.1.4. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Scale of Operation
13.1.5. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of Packaging Form
13.1.6. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of End-Users
13.1.7. Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Geography
13.1.7.1. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030
13.1.7.1.1. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Business Segment
13.1.7.1.2. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of API Manufactured
13.1.7.1.3. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of FDF Offered
13.1.7.1.4. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Scale of Operation
13.1.7.1.5. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of Packaging Form
13.1.7.1.6. Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of End-Users
13.1.7.2. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030
13.1.7.2.1. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Business Segment
13.1.7.2.2. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of API Manufactured
13.1.7.2.3. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of FDF Offered
13.1.7.2.4. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Scale of Operation
13.1.7.2.5. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of Packaging Form
13.1.7.2.6. Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of End-Users
13.1.7.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030
13.1.7.3.1. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Business Segment
13.1.7.3.2. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of API Manufactured
13.1.7.3.3. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of FDF Offered
13.1.7.3.4. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation
13.1.7.3.5. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Packagiey value ng Form
13.1.7.3.6. Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of End-Users
13.1.7.4. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030
13.1.7.4.1. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Business Segment
13.1.7.4.2. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of API Manufactured
13.1.7.4.3. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of FDF Offered
13.1.7.4.4. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Scale of Operation
13.1.7.4.5. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of Packaging Form
13.1.7.4.6. Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of End-Users
13.1.7.5. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030
13.1.7.5.1. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Business Segment
13.1.7.5.2. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of API Manufactured
13.1.7.5.3. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of FDF Offered
13.1.7.5.4. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Scale of Operation
13.1.7.5.5. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of Packaging Form
13.1.7.5.6. Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of End-Users
14. KEY INSIGHTS
14.1. Chapter Overview
14.2. Integrated Contract Service Providers (Heat Map Analysis)
14.3. Analysis by Geography
14.4. Analysis by Geography, Company Size and Business Segment
15. SWOT ANALYSIS
15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Comparison of SWOT Factors
16. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES DRUGS / THERAPIES
16.1. Chapter Overview
16.2. Small Molecule and Large Molecule Drugs / Therapies
16.2.1. Comparison of General Characteristics
16.2.2. Comparison of Key Specifications
16.2.3. Comparison of Manufacturing Processes
16.2.4. Comparison of Key Manufacturing-related Challenges
17. CONCLUDING REMARKS
18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Ajinomoto Althea
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Scott Goldstein, Ex - Director, Business Development, Drug Product Manufacturing
18.3. Bachem
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Thomas Fruh, Ex - Chief Executive Officer
18.4. CiVentiChem
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Bhaskar VenePalli, President and Chief Executive Officer
18.5. CordenPharma
18.5.1. Company Snapshot
18.5.2. Interview Transcript: Roberto Margartia, Director, Business Development
18.6. Helsinn Group
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Allison Vavala, Director, Commercial Development
18.7. Novasep
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Kevin Daley, Director, Pharmaceuticals Marketing
18.8. Sovereign Pharma
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Piyush Desai, Director, Operations
18.9. Wavelength Pharmaceuticals
18.9.1. Company Snapshot
18.9.2. Interview Transcript: Ilan Avni, Vice President Business Development, Marketing, and IP
19. APPENDIX I: TABULATED DATA
20. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Type of Contract Manufacturers
Figure 3.2 Types of Third-Party Service Providers in the Pharmaceutical Contract Manufacturing Industry
Figure 3.3 Outsourcing across Various Components of Pharmaceutical Value Chain
Figure 3.4 Services Offered by CMOs
Figure 3.5 Key Considerations While Selecting a CMO Partner
Figure 4.1 Key Regulatory Requirements for CMOs and CROs in India
Figure 4.2 Regulatory Landscape for Pharmaceutical CMOs: Distribution by Types of Regulatory Authorities
Figure 4.3 Bubble Analysis: Regional Regulatory Summary
Figure 5.1 Pharmaceutical CMOs: Distribution by Year of Establishment
Figure 5.2 Pharmaceutical CMOs: Distribution by Company Size
Figure 5.3 Pharmaceutical CMOs: Distribution by Location of Headquarters
Figure 5.4 Pharmaceutical CMOs: Distribution by Type of Business Segment
Figure 5.5 Pharmaceutical CMOs: Distribution by Type of API Manufactured
Figure 5.6 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Figure 5.7 Pharmaceutical CMOs: Distribution by Type of Molecule
Figure 5.8 Pharmaceutical CMOs: Distribution by Type of Service(s) Offered
Figure 5.9 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Offered
Figure 5.10 Pharmaceutical CMOs: Distribution by Scale of Operation
Figure 5.11 Pharmaceutical CMOs: Distribution by Location of Headquarters and Type of Service(s) Offered
Figure 5.12 Pharmaceutical CMOs: Distribution by Type of Business Segment and Type of Service(s) Offered
Figure 5.13 Pharmaceutical CMOs: Distribution by Type of Service(s) Offered and Scale of Operation
Figure 5.14 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in North America
Figure 5.15 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in Europe
Figure 5.16 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in Asia-Pacific and Rest of the World
Figure 6.1 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in North America
Figure 6.2 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in Europe
Figure 6.3 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in Asia-Pacific and Rest of the World
Figure 7.1 AMRI: Service Portfolio
Figure 7.2 Altasciences: Service Portfolio
Figure 7.3 Cambrex: Service Portfolio
Figure 7.4 Catalent: Annual Revenues, 2014-2020 (USD Million)
Figure 7.5 Catalent: Service Portfolio
Figure 7.6 DPT Laboratories: Service Portfolio
Figure 7.7 Thermo Fisher Scientific: Annual Revenues, 2014-2020 (USD Billion)
Figure 7.8 Thermo Fisher Scientific: Revenues by Business Segments, 2020 (USD Billion)
Figure 7.9 Thermo Fisher Scientific: Service Portfolio
Figure 7.10 Aenova Group: Annual Revenues 2017-2019 (EUR Million)
Figure 7.11 Aenova Group: Service Portfolio
Figure 7.12 Almac Group: Service Portfolio
Figure 7.13 Corden Pharma: Service Portfolio
Figure 7.14 Fresenius Kabi: Annual Revenues, 2014-2020 (EUR Million)
Figure 7.15 Fresenius Kabi: Revenues by Product Segments, 2020 (EUR Million)
Figure 7.16 Fresenius Kabi: Service Portfolio
Figure 7.17 Glatt: Service Portfolio
Figure 7.18 Hovione: Service Portfolio
Figure 7.19 Recipharm: Annual Revenues, 2014-2020 (SEK Million)
Figure 7.20 Recipharm: Revenues by Business Segment, 2020 (SEK Million)
Figure 7.21 Recipharm: Service Portfolio
Figure 7.22 Siegfried: Annual Revenues, 2013-2020 (CHF Million)
Figure 7.23 Siegfried: Revenues by Product Segments, 2020 (CHF Million)
Figure 7.24 Siegfried: Service Portfolio
Figure 7.25 CMIC Group: Annual Revenues, 2014 - H1 2021 (JPY Billion)
Figure 7.26 CMIC Group: Revenues by Business Segment, 2020 (JPY Billion)
Figure 7.27 CMIC Group: Service Portfolio
Figure 7.28 Nectar Lifesciences: Annual Revenues, 2014 – 2020 (INR Billion)
Figure 7.29 Nectar Lifesciences: Service Portfolio
Figure 7.30 Syngene: Annual Revenues, 2014 – 2020 (INR Billion)
Figure 7.31 Syngene: Service Portfolio
Figure 7.32 WuXi AppTec: Annual Revenues, 2015 – Q1 2021 (RMB Billion)
Figure 7.33 WuXi AppTec: Revenues by Business Segment, 2020 (RMB Billion)
Figure 7.34 WuXi AppTec: Service Portfolio
Figure 7.35 STA Pharmaceuticals (A subsidiary of WuXi AppTec): Service Portfolio
Figure 8.1 Make versus Buy Decision Making Framework
Figure 8.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 9.1 Mergers and Acquisitions: Cumulative Year-wise Distribution, 2017-2021
Figure 9.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 9.3 Acquisitions: Distribution by Type of Acquisition
Figure 9.4 Mergers and Acquisitions: Distribution by Focus Area
Figure 9.5 Mergers and Acquisitions: Distribution by Type of Business Segment
Figure 9.6 Mergers and Acquisitions: Distribution by Type of Service(s) Offered
Figure 9.7 Mergers and Acquisitions: Distribution by Scale of Operation
Figure 9.8 Mergers and Acquisitions: Distribution by Geography
Figure 9.9 Mergers and Acquisitions: Distribution by Location of Manufacturing Facility
Figure 9.10 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 9.11 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 9.12 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 9.13 Key Acquisitions: Distribution by Deal Multiples
Figure 10.1 Recent Expansions: Cumulative Year-wise Distribution, 2017-2021
Figure 10.2 Recent Expansions: Distribution by Purpose of Expansion
Figure 10.3 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 10.4 Recent Expansions: Distribution by Type of Business Segment
Figure 10.5 Recent Expansions: Distribution by Type of Molecule
Figure 10.6 Recent Expansions: Distribution by Type of Service(s) Offered
Figure 10.7 Recent Expansions: Distribution by Scale of Operation
Figure 10.8 Recent Expansions: Distribution by Capital Invested (USD Million)
Figure 10.9 Recent Expansions: Distribution by Location of Headquarters
Figure 10.10 Recent Expansions: Distribution by Purpose of Expansion and Location of Headquarters
Figure 10.11 Recent Expansions: Distribution by Location of Manufacturing Facility
Figure 10.12 Most Active Players: Distribution by Number of Expansion Initiatives
Figure 11.1 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs (Sample Data Set)
Figure 11.2 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs
Figure 11.3 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Scale of Operation
Figure 11.4 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Headquarters
Figure 11.5 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Manufacturing Facilities (Region-wise)
Figure 11.6 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 12.1 Overall Annual Demand for Small Molecule APIs, 2021-2030 (Metric Ton)
Figure 12.2 Demand for Small Molecule APIs in North America, 2021-2030 (Metric Ton)
Figure 12.3 Demand for Small Molecule APIs in Europe, 2021-2030 (Metric Ton)
Figure 12.4 Demand for Small Molecule APIs in Asia-Pacific and Rest of the World, 2021-2030 (Metric Ton)
Figure 12.5 Demand for Small Molecule APIs at Clinical Scale, 2021-2030 (Metric Ton)
Figure 12.6 Demand for Small Molecule APIs at Commercial Scale, 2021-2030 (Metric Ton)
Figure 13.1 Global Pharmaceutical Contract Manufacturing Market, 2021-2030 (USD Billion)
Figure 13.2 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Business Segment (USD Billion)
Figure 13.3 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.4 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.5 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Scale of Operation (USD Billion)
Figure 13.6 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.7 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of End-User (USD Billion)
Figure 13.8 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Geography (USD Billion)
Figure 13.9 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030 (USD Billion)
Figure 13.10 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Business Segment (USD Billion)
Figure 13.11 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.12 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.13 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.14 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.15 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of End-User (USD Billion)
Figure 13.16 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030 (USD Billion)
Figure 13.17 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Business Segment (USD Billion)
Figure 13.18 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.19 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.20 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.21 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.22 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of End-User (USD Billion)
Figure 13.23 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 13.24 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Business Segment (USD Billion)
Figure 13.25 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.26 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.27 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.28 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.29 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of End-User (USD Billion)
Figure 13.30 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030 (USD Billion)
Figure 13.31 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Business Segment (USD Billion)
Figure 13.32 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.33 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.34 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.35 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.36 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of End-User (USD Billion)
Figure 13.37 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030 (USD Billion)
Figure 13.38 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Business Segment (USD Billion)
Figure 13.39 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Figure 13.40 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Figure 13.41 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.42 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Figure 13.43 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of End-User (USD Billion)
Figure 14.1 Integrated Service Providers Heat Map Analysis: Distribution by Year of Establishment, Company Size and Geography
Figure 14.2 Pharmaceutical CMOs: Geographical Distribution by Location of Manufacturing Facilities
Figure 14.3 Pharmaceutical CMOs: Distribution by Business Segment, Company Size and Geography
Figure 15.1 Pharmaceutical Contract Manufacturing SWOT Analysis: Overview
Figure 15.2 Pharmaceutical Contract Manufacturing SWOT Analysis: Strengths
Figure 15.3 Pharmaceutical Contract Manufacturing SWOT Analysis: Weaknesses
Figure 15.4 Pharmaceutical Contract Manufacturing SWOT Analysis: Opportunities
Figure 15.5 Pharmaceutical Contract Manufacturing SWOT Analysis: Threats
Figure 15.6 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2020
Figure 16.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 17.1 Concluding Remarks: Summary of Market Landscape
Figure 17.2 Concluding Remarks: Summary of Mergers and Acquisitions
Figure 17.3 Concluding Remarks: Summary of Recent Expansions
Figure 17.4 Concluding Remarks: Summary of Capacity Analysis
Figure 17.5 Concluding Remarks: Summary of Demand Analysis
Figure 17.6 Concluding Remarks: Summary of Market Sizing and Opportunity Analysis
Table 4.1 Comparison of FDA Quality Agreement and EMA cGMP guidelines
Table 4.2 Pharmaceutical CMOs: Information on Approval from Various Regulatory Authorities
Table 4.3 Key Regulatory Authorities: Comparison of NDA Approval Characteristics
Table 5.1 List of Pharmaceutical CMOs
Table 5.2 Pharmaceutical CMOs: Information on Type of Business Segment and Type of API Manufactured
Table 5.3 Pharmaceutical CMOs: Information on Type of FDF Offered and Type of Molecule
Table 5.4 Pharmaceutical CMOs: Information on Type of Service(s) Offered
Table 5.5 Pharmaceutical CMOs: Information on Type of Primary Packaging Form Offered
Table 5.6 Pharmaceutical CMOs: Information on Scale of Operation
Table 7.1 Pharmaceutical Contract Manufacturing: List of Companies Profiled
Table 7.2 AMRI: Company Snapshot
Table 7.3 AMRI: Manufacturing Facilities
Table 7.4 AMRI: Sterile Manufacturing Facilities
Table 7.5 AMRI: Recent Developments and Future Outlook
Table 7.6 Altasciences: Company Snapshot
Table 7.7 Altasciences: Recent Developments and Future Outlook
Table 7.8 Cambrex: Company Snapshot
Table 7.9 Catalent: Company Snapshot
Table 7.10 DPT Laboratories: Company Snapshot
Table 7.11 DPT Laboratories: Manufacturing Facilities
Table 7.12 Thermo Fisher Scientific: Company Snapshot
Table 7.13 Thermo Fisher Scientific: Manufacturing Facilities
Table 7.14 Aenova Group: Company Snapshot
Table 7.15 Aenova Group: Manufacturing Facilities
Table 7.16 Almac Group: Company Snapshot
Table 7.17 Corden Pharma: Company Snapshot
Table 7.18 Corden Pharma: Manufacturing Facilities
Table 7.19 Fresenius Kabi: Company Snapshot
Table 7.20 Fresenius Kabi: Manufacturing Facilities
Table 7.21 Fresenius Kabi: Packaging Capabilities
Table 7.22 Glatt: Company Snapshot
Table 7.23 Glatt: Manufacturing Facilities
Table 7.24 Hovione: Company Snapshot
Table 7.25 Hovione: Manufacturing Facilities
Table 7.26 Hovione: Recent Developments and Future Outlook
Table 7.27 Recipharm: Company Snapshot
Table 7.28 Recipharm: Manufacturing Facilities
Table 7.29 Recipharm: Recent Developments and Future Outlook
Table 7.30 Siegfried: Company Snapshot
Table 7.31 Siegfried: Manufacturing Facilities
Table 7.32 Siegfried: Recent Developments and Future Outlook
Table 7.33 CMIC Group: Company Snapshot
Table 7.34 Nectar Lifesciences: Company Snapshot
Table 7.35 Nectar Lifesciences: Manufacturing Facilities
Table 7.36 Syngene: Company Snapshot
Table 7.37 Syngene: Manufacturing Facilities
Table 7.38 WuXi AppTec: Company Snapshot
Table 7.39 WuXi AppTec: Manufacturing Facilities
Table 7.40 WuXi AppTec: Recent Developments and Future Outlook
Table 9.1 Pharmaceutical Contract Manufacturing: List of Mergers and Acquisitions
Table 10.1 Pharmaceutical Contract Manufacturing: List of Recent Expansions
Table 11.1 Pharmaceutical Contract Manufacturing Installed Capacity: Average Capacity by Size of CMOs (Sample Data Set)
Table 11.2 Pharmaceutical Contract Manufacturing Installed Global Capacity: Distribution by Size of CMOs
Table 13.1 Ajinomoto Althea: Key Highlights
Table 13.2 Bachem: Key Highlights
Table 13.3 Batavia Biosciences: Key Highlights
Table 13.4 CiVentiChem: Key Highlights
Table 13.5 Helsinn Group: Key Highlights
Table 13.6 Novasep: Key Highlights
Table 13.7 Polymun Scientific: Key Highlights
Table 13.8 Rentschler Biopharma: Key Highlights
Table 13.9 Sovereign Pharma: Key Highlights
Table 13.10 WACKER Biotech: Key Highlights
Table 13.11 Wavelength Pharmaceuticals: Key Highlights
Table 19.1 Regulatory Landscape for Pharmaceutical CMOs: Distribution by Types of Regulatory Authorities
Table 19.2 Pharmaceutical CMOs: Distribution by Year of Establishment
Table 19.3 Pharmaceutical CMOs: Distribution by Company Size
Table 19.4 Pharmaceutical CMOs: Distribution by Location of Headquarters
Table 19.5 Pharmaceutical CMOs: Distribution by Type of Business Segment
Table 19.6 Pharmaceutical CMOs: Distribution by Type of API Manufactured
Table 19.7 Pharmaceutical CMOs: Distribution by Type of FDF Offered
Table 19.8 Pharmaceutical CMOs: Distribution by Type of Molecule
Table 19.9 Pharmaceutical CMOs: Distribution by Type of Service(s) Offered
Table 19.10 Pharmaceutical CMOs: Distribution by Type of Primary Packaging Offered
Table 19.11 Pharmaceutical CMOs: Distribution by Scale of Operation
Table 19.12 Pharmaceutical CMOs: Distribution by Location of Headquarters and Type of Service(s) Offered
Table 19.13 Pharmaceutical CMOs: Distribution by Type of Business Segment and Type of Service(s) Offered
Table 19.14 Pharmaceutical CMOs: Distribution by Type of Service(s) Offered and Scale of Operation
Table 19.15 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in North America
Table 19.16 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in Europe
Table 19.17 Pharmaceutical CMOs: Distribution of Manufacturing Facilities in Asia-Pacific and Rest of the World
Table 19.18 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in North America
Table 19.19 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in Europe
Table 19.20 Regional Distribution of Pharmaceutical Contract Manufacturing Facilities in Asia-Pacific and Rest of the World
Table 19.21 Catalent: Annual Revenues, 2014-2020 (USD Million)
Table 19.22 Thermo Fisher Scientific: Annual Revenues, 2014-2020 (USD Billion)
Table 19.23 Thermo Fisher Scientific: Revenues by Business Segments, 2020 (USD Billion)
Table 19.24 Aenova Group: Annual Revenues 2017-2019 (EUR Million)
Table 19.25 Fresenius Kabi: Annual Revenues, 2014-2020 (EUR Million)
Table 19.26 Fresenius Kabi: Revenues by Product Segments, 2020 (EUR Million)
Table 19.27 Recipharm: Annual Revenues, 2014-2020 (SEK Million)
Table 19.28 Recipharm: Revenues by Business Segment, 2020 (SEK Million)
Table 19.29 Siegfried: Annual Revenues, 2013-2020 (CHF Million)
Table 19.30 Siegfried: Revenues by Product Segments, 2020 (CHF Million)
Table 19.31 CMIC Group: Annual Revenues, 2014 - H1 2021 (JPY Billion)
Table 19.32 CMIC Group: Revenues by Business Segment, 2020 (JPY Billion)
Table 19.33 Nectar Lifesciences: Annual Revenues, 2014 – 2020 (INR Billion)
Table 19.34 Syngene: Annual Revenues, 2014 – 2020 (INR Billion)
Table 19.35 WuXi AppTec: Annual Revenues, 2015 – Q1 2021 (RMB Billion)
Table 19.36 WuXi AppTec: Revenues by Business Segment, 2020 (RMB Billion)
Table 19.37 Mergers and Acquisitions: Cumulative Year-wise Distribution, 2017-2021 (till May)
Table 19.38 Mergers and Acquisitions: Distribution by Type of Agreement
Table 19.39 Acquisitions: Distribution by Type of Acquisition
Table 19.40 Mergers and Acquisitions: Distribution by Focus Area
Table 19.41 Mergers and Acquisitions: Distribution by Type of Business Segment
Table 19.42 Mergers and Acquisitions: Distribution by Type of Service(s) Offered
Table 19.43 Mergers and Acquisitions: Distribution by Scale of Operation
Table 19.44 Mergers and Acquisitions: Distribution by Geography
Table 19.45 Mergers and Acquisitions: Distribution by Location of Manufacturing Facility
Table 19.46 Most Active Acquirers: Distribution by Number of Acquisitions
Table 19.47 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 19.48 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 19.49 Key Acquisitions: Distribution by Deal Multiples
Table 19.50 Recent Expansions: Cumulative Year-wise Distribution, 2017-2021 (till May)
Table 19.51 Recent Expansions: Distribution by Purpose of Expansion
Table 19.52 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 19.53 Recent Expansions: Distribution by Type of Business Segment
Table 19.54 Recent Expansions: Distribution by Type of Molecule
Table 19.55 Recent Expansions: Distribution by Type of Service(s) Offered
Table 19.56 Recent Expansions: Distribution by Scale of Operation
Table 19.57 Recent Expansions: Distribution by Capital Invested (USD Million)
Table 19.58 Recent Expansions: Distribution by Location of Headquarters
Table 19.59 Recent Expansions: Distribution by Purpose of Expansion and Location of Headquarters
Table 19.60 Recent Expansions: Distribution by Location of Manufacturing Facility
Table 19.61 Most Active Players: Distribution by Number of Expansion Initiatives
Table 19.62 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs (Sample Data Set)
Table 19.63 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Size of CMOs
Table 19.64 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Scale of Operation
Table 19.65 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Headquarters
Table 19.66 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Manufacturing Facilities (Region-wise)
Table 19.67 Installed Global Capacity for Pharmaceutical Contract Manufacturing: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 19.68 Overall Annual Demand for Small Molecule APIs, 2021-2030 (Metric Ton)
Table 19.69 Demand for Small Molecule APIs in North America, 2021-2030 (Metric Ton)
Table 19.70 Demand for Small Molecule APIs in Europe, 2021-2030 (Metric Ton)
Table 19.71 Demand for Small Molecule APIs in Asia-Pacific and Rest of the World, 2021-2030 (Metric Ton)
Table 19.72 Demand for Small Molecule APIs at Clinical Scale, 2021-2030 (Metric Ton)
Table 19.73 Demand for Small Molecule APIs at Commercial Scale, 2021-2030 (Metric Ton)
Table 19.74 Global Pharmaceutical Contract Manufacturing Market, 2021-2030 (USD Billion)
Table 19.75 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Business Segment (USD Billion)
Table 19.76 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.77 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.78 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Scale of Operation (USD Billion)
Table 19.79 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.80 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Type of End-User (USD Billion)
Table 19.81 Pharmaceutical Contract Manufacturing Market, 2021 and 2030: Distribution by Geography (USD Billion)
Table 19.82 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030 (USD Billion)
Table 19.83 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Business Segment (USD Billion)
Table 19.84 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.85 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.86 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 19.87 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.88 Pharmaceutical Contract Manufacturing Market in North America, 2021-2030: Distribution by Type of End-User (USD Billion)
Table 19.89 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030 (USD Billion)
Table 19.90 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Business Segment (USD Billion)
Table 19.91 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.92 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.93 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 19.94 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.95 Pharmaceutical Contract Manufacturing Market in Europe, 2021-2030: Distribution by Type of End-User (USD Billion)
Table 19.96 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030 (USD Billion)
Table 19.97 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Business Segment (USD Billion)
Table 19.98 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.99 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.100 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 19.101 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.102 Pharmaceutical Contract Manufacturing Market in Asia-Pacific, 2021-2030: Distribution by Type of End-User (USD Billion)
Table 19.103 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030 (USD Billion)
Table 19.104 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Business Segment (USD Billion)
Table 19.105 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.106 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.107 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030:Distribution by Scale of Operation (USD Billion)
Table 19.108 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.109 Pharmaceutical Contract Manufacturing Market in Latin America, 2021-2030: Distribution by Type of End-User (USD Billion)
Table 19.110 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030 (USD Billion)
Table 19.111 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Business Segment (USD Billion)
Table 19.112 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of API Manufactured (USD Billion)
Table 19.113 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of FDF Offered (USD Billion)
Table 19.114 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 19.115 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of Packaging Form (USD Billion)
Table 19.116 Pharmaceutical Contract Manufacturing Market in Middle East and North Africa, 2021-2030: Distribution by Type of End-User (USD Billion)
The following companies and organizations have been mentioned in the report.
Source 1: resultshealthcare.com/wp-content/uploads/2019/11/Outsourced-Pharmaceutical-Manufacturing-2020-White-Paper_Results-Healthcare.pdf
Source 2: www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2020
Source 3: www.contractpharma.com/issues/2020-09-01/view_features/small-molecule-drug-development-advantages-of-an-integrated-phase-based-approach/
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES